Logo image of CELC

CELCUITY INC (CELC) Stock Fundamental Analysis

NASDAQ:CELC - Nasdaq - US15102K1007 - Common Stock - Currency: USD

13.15  +0.02 (+0.15%)

Premarket: 13.48 +0.33 (+2.51%)

Fundamental Rating

1

Taking everything into account, CELC scores 1 out of 10 in our fundamental rating. CELC was compared to 571 industry peers in the Biotechnology industry. While CELC seems to be doing ok healthwise, there are quite some concerns on its profitability. CELC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CELC has reported negative net income.
In the past year CELC has reported a negative cash flow from operations.
In the past 5 years CELC always reported negative net income.
CELC had a negative operating cash flow in each of the past 5 years.
CELC Yearly Net Income VS EBIT VS OCF VS FCFCELC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

CELC has a Return On Assets of -34.42%. This is in the better half of the industry: CELC outperforms 62.75% of its industry peers.
The Return On Equity of CELC (-62.77%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.42%
ROE -62.77%
ROIC N/A
ROA(3y)-30.27%
ROA(5y)-39.98%
ROE(3y)-39.63%
ROE(5y)-47.6%
ROIC(3y)N/A
ROIC(5y)N/A
CELC Yearly ROA, ROE, ROICCELC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

CELC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELC Yearly Profit, Operating, Gross MarginsCELC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CELC has been increased compared to 1 year ago.
CELC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CELC has an improved debt to assets ratio.
CELC Yearly Shares OutstandingCELC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CELC Yearly Total Debt VS Total AssetsCELC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 1.08, we must say that CELC is in the distress zone and has some risk of bankruptcy.
CELC has a better Altman-Z score (1.08) than 67.38% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that CELC is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.65, CELC is not doing good in the industry: 77.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z 1.08
ROIC/WACCN/A
WACCN/A
CELC Yearly LT Debt VS Equity VS FCFCELC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

CELC has a Current Ratio of 10.36. This indicates that CELC is financially healthy and has no problem in meeting its short term obligations.
CELC has a Current ratio of 10.36. This is amongst the best in the industry. CELC outperforms 80.93% of its industry peers.
CELC has a Quick Ratio of 10.36. This indicates that CELC is financially healthy and has no problem in meeting its short term obligations.
CELC's Quick ratio of 10.36 is amongst the best of the industry. CELC outperforms 80.93% of its industry peers.
Industry RankSector Rank
Current Ratio 10.36
Quick Ratio 10.36
CELC Yearly Current Assets VS Current LiabilitesCELC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.40% over the past year.
EPS 1Y (TTM)4.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CELC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.06% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.32%
EPS Next 2Y-10%
EPS Next 3Y-5.06%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CELC Yearly Revenue VS EstimatesCELC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CELC Yearly EPS VS EstimatesCELC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELC Price Earnings VS Forward Price EarningsCELC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELC Per share dataCELC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

CELC's earnings are expected to decrease with -5.06% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10%
EPS Next 3Y-5.06%

More info and screens

0

5. Dividend

5.1 Amount

CELC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELCUITY INC

NASDAQ:CELC (2/21/2025, 8:07:07 PM)

Premarket: 13.48 +0.33 (+2.51%)

13.15

+0.02 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners75.35%
Inst Owner Change-88.23%
Ins Owners13.02%
Ins Owner Change0.01%
Market Cap488.26M
Analysts85.71
Price Target31.62 (140.46%)
Short Float %11.12%
Short Ratio13.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.65%
Min EPS beat(2)-5.12%
Max EPS beat(2)10.42%
EPS beat(4)3
Avg EPS beat(4)7.31%
Min EPS beat(4)-5.12%
Max EPS beat(4)12.5%
EPS beat(8)3
Avg EPS beat(8)-7.14%
EPS beat(12)3
Avg EPS beat(12)-10.67%
EPS beat(16)4
Avg EPS beat(16)-18.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.29%
PT rev (3m)7.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.2%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.26
P/tB 3.26
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-3.26
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS4.03
TBVpS4.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.42%
ROE -62.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.27%
ROA(5y)-39.98%
ROE(3y)-39.63%
ROE(5y)-47.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 190.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.36
Quick Ratio 10.36
Altman-Z 1.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)57.08%
Cap/Depr(5y)61.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.66%
EPS Next Y0.32%
EPS Next 2Y-10%
EPS Next 3Y-5.06%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.29%
EBIT Next 3Y-33.3%
EBIT Next 5YN/A
FCF growth 1Y-127.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.35%
OCF growth 3YN/A
OCF growth 5YN/A